☆ 4.3 Article

Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma

PANCREAS (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Article Surgery

Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer

Mark J. Truty et al.

Summary: This study aimed to identify predictive factors associated with operative morbidity, mortality, and survival outcomes in patients with BR/LA PDAC undergoing TNT. The results showed that independent factors associated with favorable survival outcomes in resected patients include extended duration chemotherapy, optimal post-chemotherapy CA19-9 response, and major pathologic response. Complete metabolic response highly correlated with major pathologic response in a subset of patients.

ANNALS OF SURGERY (2021)

Add to Collection

Article Oncology

Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma A Phase 2 Randomized Clinical Trial

Davendra P. S. Sohal et al.

Summary: This study aimed to evaluate the 2-year overall survival rate of perioperative chemotherapy for resectable pancreatic ductal adenocarcinoma (PDA), but did not show significant improvement compared to historical data. The 2-year overall survival rates were 47% and 48% for the two treatment arms, demonstrating adequate safety and high resectability rates with perioperative chemotherapy, as well as challenges in quality control for resectability criteria.

JAMA ONCOLOGY (2021)

Add to Collection

Article Oncology

Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial

Eva Versteijne et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

T. Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

John P. Neoptolemos et al.

LANCET (2017)

Add to Collection

Article Oncology

Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine Followed by Gemcitabine and Capecitabine/Radiation Therapy and Surgery in Locally Advanced, Unresectable Pancreatic Adenocarcinoma

William H. Sherman et al.

CANCER (2015)

Add to Collection

Article Oncology

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

Lola Rahib et al.

CANCER RESEARCH (2014)

Add to Collection

Article Oncology

A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer

Edward J. Kim et al.

CANCER (2013)

Add to Collection

Article Medicine, General & Internal

Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial

Helmut Oettle et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)

Add to Collection

Article Medicine, General & Internal

Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial

John P. Neoptolemos et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)

Add to Collection

Article Oncology

Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head

Gauri R. Varadhachary et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

Article Oncology

Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head

Douglas B. Evans et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

Article Medicine, General & Internal

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

JP Neoptolemos et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

Add to Collection

Article Oncology

Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas

WH Sherman et al.

ONCOLOGY (2001)

Add to Collection

Article Oncology

New guidelines to evaluate the response to treatment in solid tumors

F Duffaud et al.

BULLETIN DU CANCER (2000)

Add to Collection

Article Oncology

New guidelines to evaluate the response to treatment in solid Tumors

P Therasse et al.

JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.